Macrophages and neurons are targets of retinoic acid signaling after spinal cord contusion injury.
Article Details
- CitationCopy to clipboard
Schrage K, Koopmans G, Joosten EA, Mey J
Macrophages and neurons are targets of retinoic acid signaling after spinal cord contusion injury.
Eur J Neurosci. 2006 Jan;23(2):285-95.
- PubMed ID
- 16420438 [ View in PubMed]
- Abstract
The physiological reactions after spinal cord injury are accompanied by local synthesis of the transcriptional activator retinoic acid (RA). RA exerts its effects by binding to retinoic acid receptors (RAR) which heterodimerize with retinoid X receptors (RXR) and then act as ligand-activated transcription factors. To identify possible cellular targets of RA we investigated protein levels and cellular distribution of retinoid receptors in the rat spinal cord at 4, 7, 14 and 21 days after a contusion injury. In the nonlesioned spinal cord, immunoreactivity for RARalpha, RXRalpha, RXRbeta and RXRgamma was localized in the cytosol of neurons, that of RXRalpha and RXRbeta in astrocytes and that of RARalpha, RXRalpha and RXRgamma in some oligodendrocytes. After contusion injury RARalpha and all RXRs appeared in the cell nuclei of reactive microglia and macrophages. This nuclear staining began at 4 days, was most prominent at 7 and 14 days and had decreased at 21 days after injury. A similar nuclear translocation was also observed for the RARalpha, RXRalpha and RXRbeta staining in neurons situated around the border of the contusion. These observations suggest that RA participates as a signal for the physiological responses of microglia and neurons after CNS injury.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Alitretinoin Retinoic acid receptor alpha Protein Humans YesAgonistDetails Alitretinoin Retinoic acid receptor RXR-beta Protein Humans YesAgonistDetails Tretinoin Retinoic acid receptor RXR-beta Protein Humans YesAgonistDetails Tretinoin Retinoic acid receptor RXR-gamma Protein Humans YesAgonistDetails